Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Tracking major trends and clinical research in acute coronary syndrome care
Deepak Bhatt, MD, detailed several recent clinical trials that could reshape the way clinicians manage acute coronary syndrome (ACS) patients.
New drug reverses antiplatelet effects of ticagrelor, helping surgeons avoid a 'bloody mess'
Deepak Bhatt, MD, believes bentracimab could be a game-changer if it gains approval. "I think it's the sort of drug that every emergency room and ICU would have to stock," he said. "A cardiac care unit would have to stock a couple of doses, as would every cath lab."
Late-breaking cardiovascular drug trials took center stage at ACC.25
Richard Kovacs, MD, detailed some the most important late-breaking cardiology pharmacology trials presented at ACC.25.
Quality of care for heart patients does not improve in first year of ACO participation
Researchers tracked patient outcomes through the use of 15 performance measures related to hypertension, coronary artery disease, heart failure and atrial fibrillation.
Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.

New U.S. guidelines on chronic coronary disease rethink use of beta-blockers, other medications

The updated recommendations from the American College of Cardiology and American Heart Association cover a variety of topics, including patient communication, follow-up imaging, nutritional supplements and more.

Eli Lilly to acquire private equity-backed drugmaker for up to $1.9B

Versanis, founded in 2021 by a venture capital firm, is primarily known as the company behind the obesity drug bimagrumab.

Roosha Parikh, MD, advanced imaging cardiologist, St. Francis Heart Hospital, Long Island, New York, and a clinical assistant professor of medicine at the State University of New York at Stony Brook, presented in one of the ASE 2023 amyloid sessions and spoke with Cardiovascular Business about the disease.

Amyloidosis now a hot topic in cardiac imaging due to new drug treatment

Advanced cardiac imager Roosha Parikh, MD, explained that cardiac amyloidosis is regularly misdiagnosed. It can often be identified in echocardiography results, however, if physicians know how to identify it.

dipyridamole injection drug shortage heart imaging Canada

‘I have no dose for anyone right now’: Drug shortage hits cardiologists in Canada, leading to delays

“It's very important,” one cardiologist said. “This is a life-saving test and it's very frustrating that we can't access the medication.”

PHOTO GALLERY: The trends and technologies at ASE 2023

Browse through some of the many highlights from the American Society of Echocardiography's 2023 annual meeting.

Donislecel Lantidra FDA type 1 diabetes severe hypoglycemia

FDA approves first cellular therapy to treat type 1 diabetes

The new therapy, made from the pancreatic cells of deceased donors, is designed to help adult type 1 diabetes with severe hypoglycemia go a year or longer without needing to take insulin.

Colchicine Lodoco Agepha Pharma price cost

What will Lodoco cost? Looking ahead after FDA’s historic approval of colchicine for CVD

“Our pricing strategy for Lodoco is focused on helping to ensure access to as many people as possible,” an executive with Agepha Pharma told Cardiovascular Business.

The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment.

Cardiologists applaud FDA’s approval of colchicine for CVD

"The FDA's approval of colchicine confirms that we are entering a new era of patient care," said one veteran cardiologist familiar with the drug.

Pharmaceutics

Tracking major trends and clinical research in acute coronary syndrome care

New drug reverses antiplatelet effects of ticagrelor, helping surgeons avoid a 'bloody mess'

Late-breaking cardiovascular drug trials took center stage at ACC.25

Quality of care for heart patients does not improve in first year of ACO participation

Key takeaways from ACC.25: Advances in cardiovascular science